Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

BACKGROUND: Brentuximab vedotin is a CD30-directed antibody-drug conjugate. Retreatment with brentuximab vedotin monotherapy was investigated in patients with CD30-positive Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (ALCL) who relapsed after achieving complete or partial remiss...

Full description

Saved in:
Bibliographic Details
Main Authors: Bartlett, Nancy L, Chen, Robert, Fanale, Michelle A, Brice, Pauline, Gopal, Ajay, Smith, Scott E, Advani, Ranjana, Matous, Jeffrey V, Ramchandren, Radhakrishnan, Rosenblatt, Joseph D, Huebner, Dirk, Levine, Pamela, Grove, Laurie, Forero-Torres, Andres
Format: Artigo
Language:Inglês
Published: BioMed Central 2014
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3994656/
https://ncbi.nlm.nih.gov/pubmed/24642247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-7-24
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items